OCC-WCC 2024 | WCC多發病率與代謝論壇：多病聯防，守護”心”未來！
*僅供醫學專業人士閱讀參考
心臟代謝合併症作為領域的多發病，其管理策略一直是醫學研究的熱 點和難點。這類疾病涉及多個系統的病理生理變化，治療難度極大。然而，正是這些挑戰，促使我們不斷探索和創新。
在即將到來的第十八屆東方心臟病學會議（The 18th Oriental Congress of Cardiology，OCC 2024）與世界心臟病學大會（World Congress of Cardiology，WCC 2024）上，與會專家們將圍繞心臟代謝合併症的發病機制、診斷技術、治療策略以及未來發展方向展開深入研討。期待透過這次盛會，能夠推動心臟代謝合併症管理領域的研究進步，為患者帶來更多希望。
Heart metabolic syndrome, as a prevalent disease in the field of cardiovascular medicine, has always been a hot and difficult topic in medical research. These diseases involve pathophysiological changes in multiple systems, posing significant challenges in treatment. However, it is these challenges that drive us to constantly explore and innovate.
At the upcoming 18th Oriental Congress of Cardiology (OCC 2024) and the World Congress of Cardiology (WCC 2024), experts will delve deeply into the pathogenesis, diagnostic techniques, treatment strategies, and future development directions of heart metabolic syndrome. We look forward to this grand event, hoping that it will promote research progress in the management of heart metabolic syndrome and bring more hope to patients.
論壇名稱：WCC-多發病率與代謝論壇
論壇時間：2024年6月27日 星期四
論壇地點：上海國際會議中心黃河廳
論壇壇主：倫敦衛生與熱帶醫學學院Pablo Perel教授；華中科技大學同濟醫學院附屬協和醫院黃愷教授
Forum Name: WCC-Multi-morbidity and metabolism Forum
Forum Date: Thursday,June 27 2024
Forum Venue: Yellow River Hall，Shanghai International Conference Centre
Forum Chairs:
Professor Pablo Perel, University of London, London School of Hygiene & Tropical Medicine;
Professor Huang Kai, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Pablo Perel教授
黃愷教授
肥胖與胰島素抵抗
Obesity and Insulin Resistance
在當今社會，隨著生活方式的改變和營養過剩的問題日益突出，肥胖已成為一個全球性的公共衛生問題。而肥胖背後隱藏的一個關鍵病理機制，正是胰島素抵抗。
作為這一領域的權威專家，上海市糖尿病研究所的賈偉平院士將為我們深入解析胰島素抵抗與肥胖之間的緊密關係，以及這一關係如何影響並加劇心臟代謝合併症這一多發病的發生與發展。
In todays society, with the changing lifestyles and the increasingly prominent issue of nutritional excess, obesity has become a global public health concern. A key pathological mechanism underlying obesity is insulin resistance.
Academician Jia Weiping, an authoritative expert in this field from the Shanghai Diabetes Institute, will delve into the close relationship between insulin resistance and obesity, as well as how this relationship affects and exacerbates the occurrence and development of the prevalent heart metabolic syndrome.
糖尿病“加碼”心血管疾病風險
Diabetes Increases the Risk of Cardiovascular Diseases
在中國，心血管疾病的發病率與致死率持續高居不下，成為威脅國民健康的頭號殺手。據《中國心血管健康與疾病報告2022》顯示，心血管疾病現患人數已超3.3億，每十秒鐘就有一人因心血管疾病離世。
其中，糖尿病作為心血管疾病的重要風險因素，其負擔不容忽視。糖尿病患者罹患心血管疾病，尤其是動脈粥樣硬化性心血管疾病（ASCVD）的風險大幅上升。華中科技大學同濟醫學院附屬協和醫院的黃愷教授將詳細闡述這一沉重的糖尿病負擔，以期探尋出新的保護心血管健康的有效路徑。
In China, the incidence and mortality rates of cardiovascular diseases continue to rank at the top, posing a significant threat to national health. According to the "China Cardiovascular Health and Diseases Report 2022," the number of people currently suffering from cardiovascular diseases has exceeded 330 million, and every ten seconds, someone dies from cardiovascular diseases.
Among these, diabetes serves as a significant risk factor for cardiovascular diseases, and its burden cannot be overlooked. The risk of developing cardiovascular diseases, especially atherosclerotic cardiovascular diseases (ASCVD), is significantly increased for diabetic patients. Professor Huang Kai from the Union Hospital affiliated with Tongji Medical College of Huazhong University of Science and Technology will elaborate on this heavy burden of diabetes, aiming to explore new effective paths for protecting cardiovascular health.
管理新方法，重獲健康！
New Management Approaches for Regaining Health!
在應對複雜且多發的心臟代謝合併症挑戰時，科研界正積極探索新的管理策略。哈佛大學醫學院的Evan Rosen教授將揭示一種創新的方法：透過催產素能交感神經元群來控制脂肪分解，這不僅深化了我們對脂肪代謝調控機制的理解，更為心臟代謝合併症的管理提供了強有力的新工具。
同時，美國德州大學西南醫學中心的Jay D Horton教授將引領我們探索PCSK9從基因研究到實際治療的轉化之旅。PCSK9作為調控膽固醇代謝的核心因子，其基因變異對心臟代謝健康有著深遠影響。Horton教授的報告將揭示如何從基因層面出發，精準地治療心臟代謝合併症。
In addressing the complex and prevalent challenges of heart metabolic syndrome, the scientific community is actively exploring new management strategies. Professor Evan Rosen from the United States will reveal an innovative method: controlling fat decomposition through oxytocin-sensitive sympathetic neurons, which not only deepens our understanding of the regulatory mechanism of fat metabolism but also provides a powerful new tool for managing heart metabolic syndrome.
Meanwhile, Professor Jay D Horton from UT Southwestern Medical Center will guide us through the journey of PCSK9 from genetic research to practical treatment. As a core factor regulating cholesterol metabolism, genetic variations in PCSK9 have profound impacts on heart metabolic health. Professor Hortons report will reveal how to precisely treat heart metabolic syndrome from the genetic perspective.
在WCC-多發病率與代謝論壇即將揭幕之際，我們對這場匯聚全球智慧與力量的盛會充滿了無限的期待。這不僅僅是一場學術交流的盛會，更是心血管健康事業砥礪前行的重要里程碑。我們堅信，透過此次論壇的深入研討與交流，我們將迎來對心臟代謝合併症這一多發病的全新認識和策略。這些新的見解和方法，將為我們提供更精準、更有效的治療方案，為患者帶來希望與生機！
As the WCC-Multimorbidity and Metabolism Forum is set to kick off, we are filled with immense anticipation for this event that brings together global wisdom and strength. This is not just an academic exchange event, but also an important milestone for the advancement of cardiovascular health. We firmly believe that through in-depth discussions and exchanges at this forum, we will gain new insights and strategies for the prevalent heart metabolic syndrome. These new perspectives and methods will provide us with more precise and effective treatment options, bringing hope and vitality to patients!
歡迎註冊
會議時間：2024年6月27-30日
會議地點：上海國際會議中心
註冊官網：www.occmd.org
Conference Dates：June 27-30, 2024
Conference Venue：Shanghai International Convention Center
Registration Website：www.occmd.org
更多心血管精彩內容
快來“醫生站網頁版”瞧一瞧
精彩資訊等你來
稽核：黃愷、錢菊英、陸國 平、徐亞偉
責任編輯：葉子
*"醫學界"力求所發表內容專業、可靠，但不對內容的準確性做出承諾；請相關各方在採用或以此作 為決策依據時另行核查。